Design Therapeutics (DSGN) Short Interest Ratio & Short Volume → This is the best new way to score with AI (From Weiss Ratings) (Ad) Free DSGN Stock Alerts $4.51 +0.02 (+0.45%) (As of 05/15/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Design Therapeutics Short Interest DataCurrent Short Volume2,990,000 sharesPrevious Short Volume2,390,000 sharesChange Vs. Previous Month+25.10%Dollar Volume Sold Short$10.52 millionShort Interest Ratio / Days to Cover9.8Last Record DateApril 30, 2024Outstanding Shares56,490,000 sharesFloat Size33,020,000 sharesShort Percent of Float9.06%Today's Trading Volume112,843 sharesAverage Trading Volume279,335 sharesToday's Volume Vs. Average40% Short Selling Design Therapeutics ? Sign up to receive the latest short interest report for Design Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatDSGN Short Interest Over TimeDSGN Days to Cover Over TimeDSGN Percentage of Float Shorted Over Time Ad Manward PressAmazon's betting big on this unknown AI companyAmazon's Betting Big on This Unknown AI Company Amazon has just made a stunning $144 million investment in one small AI company.Discover why this company Design Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/20242,990,000 shares $10.52 million +25.1%9.1%9.8 $3.52 4/15/20242,390,000 shares $9.06 million +7.2%7.2%9.3 $3.79 3/31/20242,230,000 shares $8.99 million +4.2%6.8%9 $4.03 3/15/20242,140,000 shares $5.52 million -24.9%6.5%8.2 $2.58 2/29/20242,850,000 shares $7.92 million +1.1%8.8%11.3 $2.78 2/15/20242,820,000 shares $7.16 million +16.1%8.7%9 $2.54 Get the Latest News and Ratings for DSGN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Design Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/31/20242,430,000 shares $5.76 million -3.2%7.5%6.2 $2.37 1/15/20242,510,000 shares $6.12 million -11.0%7.7%5.8 $2.44 12/31/20232,820,000 shares $7.47 million +9.7%8.7%6.6 $2.65 12/15/20232,570,000 shares $6.58 million -19.2%7.9%6.1 $2.56 11/30/20233,180,000 shares $7.63 million +1.6%9.8%7.4 $2.40 11/15/20233,130,000 shares $7.26 million +0.3%9.6%5.2 $2.32 10/31/20233,120,000 shares $6.36 million +6.1%9.6%3.3 $2.04 10/15/20232,940,000 shares $6.29 million +0.7%9.0%3.2 $2.14 9/30/20232,920,000 shares $6.89 million +2.1%9.0%3.2 $2.36 9/15/20232,860,000 shares $7.35 million +24.4%8.8%3.2 $2.57 8/31/20232,300,000 shares $5.70 million -42.2%7.1%2.6 $2.48 8/15/20233,980,000 shares $8.62 million -41.0%12.2%6.2 $2.17 7/31/20236,750,000 shares $54.95 million -2.3%20.8%30.3 $8.14 7/15/20236,910,000 shares $47.96 million -0.4%21.3%26.7 $6.94 6/30/20236,940,000 shares $43.72 million -7.2%21.3%26.4 $6.30 6/15/20237,480,000 shares $40.99 million +5.2%23.0%27.1 $5.48 5/31/20237,110,000 shares $40.03 million -5.0%21.9%19.9 $5.63 5/15/20237,480,000 shares $50.94 million +35.5%23.0%19.1 $6.81 4/30/20235,520,000 shares $35.60 million +2.6%17.0%13.1 $6.45 4/15/20235,380,000 shares $27.92 million -3.2%16.5%12 $5.19 3/31/20235,560,000 shares $32.08 million -23.9%17.1%12.4 $5.77 3/15/20237,310,000 shares $51.24 million -3.1%22.5%15.4 $7.01 2/28/20237,540,000 shares $53.31 million +5.2%23.2%13.1 $7.07 2/15/20237,170,000 shares $49.26 million -1.2%22.1%12.7 $6.87 1/31/20237,260,000 shares $56.99 million +8.2%25.1%13.2 $7.85 1/15/20236,710,000 shares $60.39 million +3.1%20.7%12.6 $9.00 12/30/20226,510,000 shares $66.79 million +28.9%21.2%12.9 $10.26 12/15/20225,050,000 shares $40.96 million +11.5%20.2%9.8 $8.11 11/30/20224,530,000 shares $63.42 million -10.7%14.3%11.2 $14.00 11/15/20225,070,000 shares $72.30 million -1.7%16.0%14.5 $14.26 10/31/20225,160,000 shares $80.60 million +7.3%16.6%15.6 $15.62 10/15/20224,810,000 shares $75.90 million -11.4%15.5%16.1 $15.78 9/30/20225,430,000 shares $90.79 million +23.7%17.5%19.6 $16.72 9/15/20224,390,000 shares $99.78 million +10.6%14.1%16.6 $22.73The #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique Way (Ad)Nanoviricides Technology Will Transform The Way Viruses & Their Variants Are Treated Worldwide And This Company Is At The Forefront!See how with its ongoing expansion and development DSGN Short Interest - Frequently Asked Questions What is Design Therapeutics' current short interest? Short interest is the volume of Design Therapeutics shares that have been sold short but have not yet been closed out or covered. As of April 30th, traders have sold 2,990,000 shares of DSGN short. 9.06% of Design Therapeutics' shares are currently sold short. Learn More on Design Therapeutics' current short interest. What is a good short interest ratio for Design Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. DSGN shares currently have a short interest ratio of 10.0. Learn More on Design Therapeutics's short interest ratio. Which institutional investors are shorting Design Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Design Therapeutics: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Design Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 9.06% of Design Therapeutics' floating shares are currently sold short. Is Design Therapeutics' short interest increasing or decreasing? Design Therapeutics saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 2,990,000 shares, an increase of 25.1% from the previous total of 2,390,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Design Therapeutics' float size? Design Therapeutics currently has issued a total of 56,490,000 shares. Some of Design Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Design Therapeutics currently has a public float of 33,020,000 shares. How does Design Therapeutics' short interest compare to its competitors? 9.06% of Design Therapeutics' shares are currently sold short. Here is how the short interest of companies compare to Design Therapeutics: Immutep Limited (3.06%), Akebia Therapeutics, Inc. (5.66%), Aldeyra Therapeutics, Inc (4.03%), Pyxis Oncology, Inc. (3.95%), Omeros Co. (24.41%), 2seventy bio, Inc. (14.59%), G1 Therapeutics, Inc. (5.41%), ESSA Pharma Inc. (2.09%), Foghorn Therapeutics Inc. (7.05%), Emergent BioSolutions Inc. (14.13%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Design Therapeutics stock? Short selling DSGN is an investing strategy that aims to generate trading profit from Design Therapeutics as its price is falling. DSGN shares are trading up $0.02 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Design Therapeutics? A short squeeze for Design Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of DSGN, which in turn drives the price of the stock up even further. How often is Design Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including DSGN, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: Immutep Short Interest Akebia Therapeutics Short Interest Aldeyra Therapeutics Short Interest Pyxis Oncology Short Interest Omeros Short Interest 2seventy bio Short Interest G1 Therapeutics Short Interest ESSA Pharma Short Interest Foghorn Therapeutics Short Interest Emergent BioSolutions Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:DSGN) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin AnalyticsTop 5 AI Stocks to Buy for 2024Market Moving TrendsThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportTop 5 Tech Stocks to Buy for 2024Daily Market AlertsShocking $16T Elon Musk Crypto LeakCrypto 101 Media